Lytix successfully recruits for trial of drug for advanced melanoma
Immuno-oncology company Lytix Biopharma has announced completion of patient recruitment in the ATLAS-IT-05 trial, designed to assess the efficacy of LTX-315 in patients with advanced melanoma